Start Date
March 31, 2011
Primary Completion Date
December 31, 2014
Study Completion Date
December 31, 2014
Ceplene®, IL-2, Azacitidine
Azacitidine: 75 mg/m2 subcutaneously daily for 7 days every 4 weeks. Ceplene® / IL2: Patients will receive Ceplene at 0.5 mg subcutaneous twice daily and human recombinant IL-2 at 16 400 U/kg subcutaneous twice daily during 15 days for up to 10 cycles, on days 8 to 21 of AZA cycles.
Azacitidine
Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks
Hôpital Paoli-Calmettes, Marseille
CHU de Caen, Caen
Hopital Bretonneau, Tours
CHU Grenoble, Grenoble
CHU Angers, Angers
Hematology Dpt, Hopital de l'Hotel Dieu, Nantes
CHRU de Reims, Reims
Hôpital Saint Vincent, Lille
CHRU Hurriez, Lille
CHU de, Clermont-Ferrand
Hôpital de la Côte Basque, Bayonne
Centre Hospitalier Joffre, Perpignan
Centre Hospitalier Universitaire de STRASBOURG, Strasbourg
Hôpital Edouard Heriot, dpt Hématologie Clinique, Lyon
Hopital Saint Louis, Paris
Hôpital Saint Antoine, Paris
CHU Cochin, Paris
Centre Henri Bequerel, Rouen
Hôpital Versailles, Le Chesnay
CHU d'Amiens, Amiens
CH d'Avignon, Avignon
Hôpital Jean-Bernard, Poitiers
CHRU Limoges, Limoges
Centre Hospitalier Sud-Francilien, Corbeil-Essonnes
Hopital Avicenne, Bobigny
CHU de Bicêtre, Le Kremlin-Bicêtre
CHU Archet, Nice
Hopital Purpan Service d'Hématologie Clinique, Toulouse
Collaborators (1)
EpiCept Corporation
INDUSTRY
Groupe Francophone des Myelodysplasies
OTHER